✦ LIBER ✦

412 Antitumor Activity of BM-1197, a Dual Inhibitor of Bcl-2 and Bcl-xL, in Small Cell Lung Cancer Tumors

✍ Scribed by Bai, L.; Chen, J.; McEachern, D.; Liu, L.; Zhou, H.; Aguilar, A.; Yang, C.Y.; Meagher, J.L.; Stuckey, J.A.; Wang, S.

Book ID: 122449153
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 62 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72210-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic value of immunohistochemical

Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers

✍ A M Groeger; V Esposito; A De Luca; R Cassandro; G Tonini; V Ambrogi; F Baldi; R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB

Simultaneous evaluation of viability and

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer

✍ A. Santos; A. B. Sarmento-Ribeiro; M. C. Pedroso de Lima; S. Simões; J. N. Morei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 669 KB

567 Antisense-mediated downregulation of

567 Antisense-mediated downregulation of BCL-2 and BCL-XL expression in lung cancer cell lines: Biologic implication and potential therapeutic benefit

✍ Zangemeister-Wittke, U.; Ziegler, A.; Luedke, G.H.; Stahel, R.A. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 295 KB

A small inhibitor of the interaction bet

A small inhibitor of the interaction between Bax and Bcl-XLcan synergize with methylprednisolone to induce apoptosis in Bcl-XL-overexpressing breast-cancer cells

✍ Yee-Joo Tan; Eileen Teng; Anthony E. Ting 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 504 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct